Biomedicines (Jan 2023)

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing

  • Alessandra Sperotto,
  • Maria Teresa Bochicchio,
  • Giorgia Simonetti,
  • Francesco Buccisano,
  • Jacopo Peccatori,
  • Simona Piemontese,
  • Elisabetta Calistri,
  • Giulia Ciotti,
  • Elisabetta Pierdomenico,
  • Roberta De Marchi,
  • Fabio Ciceri,
  • Michele Gottardi

DOI
https://doi.org/10.3390/biomedicines11020359
Journal volume & issue
Vol. 11, no. 2
p. 359

Abstract

Read online

It has now been ascertained that acute myeloid leukemias—as in most type of cancers—are mixtures of various subclones, evolving by acquiring additional somatic mutations over the course of the disease. The complexity of leukemia clone architecture and the phenotypic and/or genotypic drifts that can occur during treatment explain why more than 50% of patients—in hematological remission—could relapse. Moreover, the complexity and heterogeneity of clone architecture represent a hindrance for monitoring measurable residual disease, as not all minimal residual disease monitoring methods are able to detect genetic mutations arising during treatment. Unlike with chemotherapy, which imparts a relatively short duration of selective pressure on acute myeloid leukemia clonal architecture, the immunological effect related to allogeneic hematopoietic stem cell transplant is prolonged over time and must be overcome for relapse to occur. This means that not all molecular abnormalities detected after transplant always imply inevitable relapse. Therefore, transplant represents a critical setting where a measurable residual disease-based strategy, performed during post-transplant follow-up by highly sensitive methods such as next-generation sequencing, could optimize and improve treatment outcome. The purpose of our review is to provide an overview of the role of next-generation sequencing in monitoring both measurable residual disease and clonal evolution in acute myeloid leukemia patients during the entire course of the disease, with special focus on the transplant phase.

Keywords